RCPT up +6.75% percent Today $RCPT High is at 111.70 and

New Post Public Reply Private Reply Replies (0) Message Board

Nov 19, 2014 at 10:33 AM

RCPT up +6.75% percent Today $RCPT High is at 111.70 and the Low 102.70 with current volume of 951,641.

Recent News posted below.

Receptos Inc RCPT other info.
http://investorshangout.com/Receptos-Inc-RCPT-87962/

RCPT Receptos Inc Recent Headline News

Receptos prices stock offering
Seeking Alpha - at Seeking Alpha - 2 hrs 31 mins ago

RCPT: 109.51 (+6.53)

Receptos Announces Pricing of Underwritten Public Offering of Common Stock
GlobeNewswire - Tue Nov 18, 7:10PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public of $100.00 per share. The gross proceeds to Receptos from this offering are expected to be $360 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares of common stock to be sold in the offering are being offered by Receptos. In addition, Receptos has granted the underwriters a 30-day option to purchase up to an additional 540,000 shares of common stock. The offering is expected to close on or about November 24, 2014, subject to customary closing conditions.
RCPT: 109.51 (+6.53)

Today In SA PRO: Monday, November 17
SA PRO Top Ideas - Seeking Alpha - Tue Nov 18, 4:00AM CST
Top Idea: Edgewater Technologies by Andreas: Long / Micro-Cap / IT Services / Value / Cyclical Swing / Takeover Target / Outstanding Performance Award Winning Buyside Author / 75% Upside Top Idea: Sungy Mobile by Radiant Research: Short /...
DFS: 64.21 (-0.77), DTSI: 31.83 (-0.86), GOMO: 5.94 (-0.26), GBX: 64.49 (+0.04), EDGW: 8.10 (+0.13), RCPT: 109.51 (+6.53)

Receptos Announces Proposed Underwritten Public Offering of Common Stock
GlobeNewswire - Mon Nov 17, 3:01PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today that it intends to offer shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by Receptos. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
RCPT: 109.51 (+6.53)

Announcing This Week's Outstanding Performance Award Winners - Stephen Simpson And Trading The Spread
SA Editor Daniel Shvartsman - Seeking Alpha - Mon Nov 17, 4:00AM CST
Dear readers, This week's winners of our Outstanding Performance awards share, as per usual, a few key common traits. Both authors are regular and successful authors on Seeking Alpha. Both articles were compelling cases made for undervaluation in...
GBX: 64.49 (+0.04), RCPT: 109.51 (+6.53)

InsiderInsights.com Daily Round Up 11/12/14: DVA, PSEC, MRC, SUMR
InsiderInsights - at Seeking Alpha - Fri Nov 14, 3:44PM CST

HAS: 56.14 (+0.02), CJES: 17.89 (-0.09), FB: 73.70 (-0.64), MRC: 21.59 (-0.21), SUMR: 2.78 (-0.05), MYL: 54.88 (-1.36), GOOG: 532.22 (-2.81), GSAT: 2.67 (+0.12), CHRS: 13.31 (+0.15), GGP: 26.08 (+0.17), DVA: 74.98 (-0.25), Q: 57.63 (+0.30), SPW: 92.60 (-0.18), RCPT: 109.51 (+6.53), DATA: 79.45 (-2.65), X: 34.93 (-1.07), PSEC: 9.61 (-0.07), SCHW: 28.48 (-0.28), ERII: 4.99 (+0.09)

Tocagen Appoints Faheem Hasnain as Chairman of the Board of Directors
PR Newswire - Fri Nov 14, 7:00AM CST
Tocagen Inc., a clinical-stage selective cancer immunotherapy company, today announced that Faheem Hasnain, president and chief executive officer of Receptos, Inc. (Nasdaq: RCPT), has been appointed as chairman of the board of directors.
RCPT: 109.51 (+6.53)

Insider Trading Alert - RCPT, EA And FFIV Traded By Insiders
at The Street - Thu Nov 13, 11:30AM CST
Stocks with insider trader activity include RCPT, EA and FFIV
EA: 42.44 (-0.43), FFIV: 127.10 (-0.74), RCPT: 109.51 (+6.53)

Receptos to Present at Credit Suisse Healthcare Conference
GlobeNewswire - Thu Nov 06, 3:03PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Credit Suisse Healthcare Conference at The Biltmore Hotel in Phoenix, Arizona. The presentation is scheduled for Wednesday, November 12 at 8:30am. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 109.51 (+6.53)

Receptos' (RCPT) CEO Faheem Hasnain on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 11:46AM CST

RCPT: 109.51 (+6.53)

Receptos posts 3Q loss
Automated Insights - Tue Nov 04, 7:19AM CST
SAN DIEGO (AP) _ Receptos Inc. (RCPT) on Tuesday reported a loss of $32.2 million in its third quarter.
RCPT: 109.51 (+6.53)

Receptos misses by $0.23, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 6:04AM CST

RCPT: 109.51 (+6.53)

Receptos Provides Development Updates and Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 6:00AM CST
- Recent positive Phase 2 induction results for TOUCHSTONE trial of RPC1063 in ulcerative colitis (UC) support initiation of broad program in inflammatory bowel disease -
RCPT: 109.51 (+6.53)

Receptos to Present at Nomura BioPharma Conference
GlobeNewswire - Mon Nov 03, 3:01PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Nomura BioPharma Conference at the Mandarin Oriental Hotel in Boston. The presentation is scheduled for Thursday, November 6 at 2:15pm Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 109.51 (+6.53)

Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion
PR Newswire - Fri Oct 31, 7:40AM CDT
Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.
ABT: 43.58 (-0.12), WMGI: 28.61 (-0.33), CFN: 57.74 (-0.04), UTHR: 128.30 (+0.09), RCPT: 109.51 (+6.53), WMGIZ: 4.41 (-0.04)

Receptos to Hold Third Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Wed Oct 29, 3:12PM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce financial results for the third quarter ended September 30, 2014 on Tuesday, November 4 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time (5:00 a.m. Pacific time).
RCPT: 109.51 (+6.53)

Receptos (RCPT) Worth Watching: Stock Moves Up 41.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:39AM CDT
Receptos, Inc. (RCPT) was a big mover last session, as its shares rose over 41% on the day.
LCI: 46.15 (-0.55), PTLA: 26.67 (-0.62), RCPT: 109.51 (+6.53), IG: 9.17 (-0.10)

Nasdaq stocks posting largest percentage increases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
VDSI: 26.33 (-0.65), ECHO: 26.32 (-0.29), LAYN: 6.88 (-0.22), NVAX: 4.90 (-0.11), SCYX: 9.05 (-0.45), RCPT: 109.51 (+6.53), TRNX: 26.28 (-0.24), IDTI: 17.92 (-0.14), SANM: 24.65 (+0.03)

Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 7.02 (-0.05), KSS: 57.18 (+0.05), MU: 32.72 (-0.15), PFE: 30.47 (-0.12), HAL: 48.11 (-0.43), AMGN: 161.24 (-1.00), NQ: 6.92 (-0.08), RGC: 22.68 (-0.13), MS: 35.27 (-0.20), MSG: 72.75 (-0.46), NVAX: 4.90 (-0.11), CQB: 14.46 (-0.01), SRPT: 15.40 (-0.17), RCPT: 109.51 (+6.53), TWTR: 39.84 (-0.77), PTIE: 1.69 (-0.04)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hi3D Unlocks AI 3D Model for Open-Source Innovation

A New Era in 3D Model Accessibility Unless you’ve been hiding under a rock, it’s hard to miss how digital terraforming has shifted gears. With Hi3D V1.0 opening its doors, the playing field's getting a major reshuffle. Or, as they say, the table is being set, and everyone's getting a seat. By letting loose production-validated AI tools, Hi3D is throwing down the...

Unicycive's Stock Plunge: Fraud Suit and FDA Hurdles

Unicycive's Tumultuous Journey Lately, it's been a rocky road for Unicycive Therapeutics, Inc., with their stock free-falling 39.1% in the span of a heartbeat on June 30, 2026. What sparked this nosedive? The FDA kicked back their revised New Drug Application for a kidney disease treatment yet again, spotlighting old manufacturing issues never nipped in the bud. Talk...

NYC's Carriage Horse Ban: A New Era for Urban Welfare

You've got to hand it to New York City—this isn't just another Tuesday twist. The City Council's decision to nix horse-drawn carriages is like throwing a wrench in an antique machine. It's a bold move in a concrete jungle that's constantly wearing new coats. Tradition vs. Welfare: The Crux For years, the idea of horses prancing down NYC streets seemed like a quaint nod...

Basic Invite's Holiday Card Service Offers Saving Time

Getting the Cards Out: Maneuvering the Holiday Hustle Alright, let's dive into the madness that is holiday card season. Could be a logistical nightmare or a nostalgic tradition, depending on your cup of tea. Basic Invite here is trying to cut through the chaos by bumping deadlines and offering some straight-out-the-gate mailing options. If you play your cards right—pun...

D-Wave Investors Face Pressure Ahead of December 15

Investors Eye December 15 Deadline Nothing like a looming deadline to stir up some anxiety among investors, and that's exactly what's going down at D-Wave Quantum Inc. right now. We're talking about the class action lawsuit spearheaded by the firm Robbins Geller Rudman & Dowd LLP. They've sent out a call to arms for investors who suffered significant losses from February...

Celebrating Alexander Trost: A Lifetime of Compassionate Care

A Legendary Career in Palliative Medicine You know, in a world where people glamorize stock flips and flashy earnings, it's refreshing to spotlight good old-fashioned compassion. Enter Dr. Alexander Trost, DNP, FNP-C, ACHPN. This fella has just been honored as a Pinnacle Lifetime Member by The Inner Circle—a nod to his impactful work in palliative medicine. You ever try...

Tigo Energy Faces Class Action Over Revenue Claims

Trouble Brewing for Tigo Energy? Straight from the horse's mouth, we hear about Tigo Energy (NASDAQ: TYGO) getting embroiled in a class action smackdown. Picture it: Tigo fumbles their projections, and boy does it sting. They're caught in the crossfire for allegedly puffing up their revenue expectations tied to a venture with EG4 Electronics—poised to churn out...

Rising Food Safety Stars Honored: A Global Effort

Food Safety Breakthrough: Youth Leads the Charge When it comes to food safety, it’s about time the younger crowd gets their due. The latest crew to step up to the plate is the Class of 2026's 40 Under 40 Food Safety Professionals. They’re not just pushing paper; these folks are setting the bar high and innovating across continents with real, tangible changes. From...

Ellington's Q3 Earnings Call: What Investors Need to Know

An Anticipated Unveiling Ellington Financial Inc. (NYSE:EFC) is gearing up to spill the beans on its third-quarter financials for 2026. It's all going down after the markets close on November 4th. I can tell you, folks, anyone keeping an eye on EFC will be itching to know what's inside those numbers. With a company this deep into financial assets, reading between the...

Dott's Q3 2026: Micromobility Growth Soars High

Riding the Wave of Profit in Micromobility Sometimes all you need is a quick jolt of genius to turn the wheels of fortune. Dott seems to have hit that sweet spot in Q3 of 2026. Deploying 45,000 new vehicles wasn’t just a logistical feat; it was a calculated bet that paid off handsomely, bolstering their business to soaring heights. Performance that Packs a Punch The Q3...